Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
This study has been completed.
Sponsored by: Yokohama City University Medical Center
Information provided by: Yokohama City University Medical Center
ClinicalTrials.gov Identifier: NCT00295555
  Purpose

Few studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure and regulation of sympathetic nervous activity in hypertensive patients with diabetic nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in diabetic nephropathy patients and compare the results with those in patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy.


Condition Intervention Phase
Diabetes Mellitus
Essential Hypertension
Renal Failure
Drug: Effects of doxazosin on morning surge in diabetic patients
Phase IV

MedlinePlus related topics: Diabetes Diabetic Kidney Problems High Blood Pressure
Drug Information available for: Doxazosin Doxazosin mesylate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title: Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy

Further study details as provided by Yokohama City University Medical Center:

Primary Outcome Measures:
  • Normalization of high blood pressure [ Time Frame: One year ]

Enrollment: 98
Study Start Date: January 2004
Study Completion Date: April 2007
Detailed Description:

The study is an open-labeled parallel prospective trial comparing the effects of doxazosin (2-8 mg/day) on 24-h blood pressure and autonomic nervous activity. Hypertensive patients with non-insulin-dependent diabetic nephropathy, patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy undergo ambulatory blood pressure monitoring before and after treatment with doxazosin. Simultaneously, spectral analysis is performed to calculate the high frequency components as a marker of parasympathetic nervous activity, and the low frequency components/high frequency components ratios as an index of the sympathovagal balance.

  Eligibility

Ages Eligible for Study:   20 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertensive patients with diabetes mellitus
  • Hypertensive patients
  • Hypertensive patients with renal disease

Exclusion Criteria:

  • Cardiac, hematologic or hepatic disease
  • Renal insufficiency (serum creatinine values> 2 mg/L)
  • Hormone-induced hypertension
  • Cerebral infarction or hemorrhage
  • Other major diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00295555

Locations
Japan
Yokohama City University Center Hospital
Yokohama, Japan, 232-0024
Sponsors and Collaborators
Yokohama City University Medical Center
Investigators
Principal Investigator: Gen Yasuda, MD Yokohama City University Center Hospital
Principal Investigator: Gen Yasuda, MD Yokohama City University Center Hospital
  More Information

Publications:
Study ID Numbers: 7332-2
Study First Received: February 21, 2006
Last Updated: May 8, 2007
ClinicalTrials.gov Identifier: NCT00295555  
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Yokohama City University Medical Center:
ambulatory blood pressure monitoring
doxazosin
alpha1-adrenergic antagonists
sympathetic nervous activity
diabetic nephropathy
essential hypertension
power spectral analysis
morning surge

Study placed in the following topic categories:
Renal Insufficiency
Diabetic Nephropathies
Metabolic Diseases
Diabetes Mellitus
Vascular Diseases
Endocrine System Diseases
Doxazosin
Urologic Diseases
Essential hypertension
Endocrinopathy
Kidney Diseases
Metabolic disorder
Glucose Metabolism Disorders
Diabetes Complications
Kidney Failure
Hypertension

Additional relevant MeSH terms:
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Therapeutic Uses
Physiological Effects of Drugs
Adrenergic Antagonists
Cardiovascular Diseases
Adrenergic alpha-Antagonists
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009